Semaglutide Boosts Kidney Outcomes With Obesity and Cardiovascular Disease

At prespecified 104-week time point, semaglutide was associated with lesser decline in eGFR than placebo.

Related Keywords

Stockholm ,Sweden ,Edinburgh ,City Of ,United Kingdom ,Helenm Colhoun , ,Novo Nordisk ,University Of Edinburgh ,European Renal Association Congress ,Healthday News ,